03/16/23 4:10 PMNasdaq : EDSA conferenceslow floatEdesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual MeetingEdesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD)RHEA-AIneutral
03/15/23 8:10 AMNasdaq : EDSA clinical triallow floatEdesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug StudyEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stageRHEA-AIneutral
02/10/23 9:00 AMNasdaq : EDSA earningslow floatEdesa Biotech Reports Fiscal 1st Quarter 2023 ResultsEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business.RHEA-AIvery positive
02/01/23 8:15 AMNasdaq : EDSA clinical triallow floatEdesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo StudyEdesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases,RHEA-AIneutral
01/17/23 8:30 AMNasdaq : EDSA clinical triallow floatEdesa Biotech Reports Topline Phase 2b Results for Dermatology DrugEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stageRHEA-AIneutral
12/20/22 8:30 AMNasdaq : EDSA low floatFDA Grants Fast Track to Edesa Biotech's ARDS Drug CandidateEdesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory andRHEA-AIvery positive
12/16/22 9:00 AMNasdaq : EDSA earningslow floatEdesa Biotech Reports Fiscal Year 2022 ResultsEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2022 and provided an update on its business.RHEA-AIpositive
12/02/22 8:00 AMNasdaq : EDSA conferenceslow floatEdesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology ConferenceEdesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will participate in a panel discussion and host one-on-oneRHEA-AIneutral
11/03/22 9:00 AMNasdaq : EDSA low floatEdesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-MarketEdesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing a private placement directly with investors priced at-the-marketRHEA-AIneutral
09/30/22 8:00 AMNasdaq : EDSA clinical triallow floatEdesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug StudyEdesa Biotech, Inc.RHEA-AIneutral